Cardiovascular
By Samir Levin · June 3, 2026 · 7 min read
Most people think of arteries as rigid pipes that either work or don't. The reality is more dynamic — and more hopeful. Two enzymes derived from fermented foods have accumulated enough clinical evidence to warrant serious attention from anyone interested in cardiovascular longevity.
This is what the research actually shows about nattokinase and serrapeptase — not the marketing version, but the data.
Nattokinase is a serine protease extracted from natto, a Japanese fermented soybean dish. It was first identified by Dr. Hiroyuki Sumi in 1987, who discovered it could dissolve fibrin — the protein scaffold of blood clots — more effectively than plasmin, the body's own clot-dissolving enzyme.
Its primary mechanisms:
These aren't theoretical effects. A 2017 randomized controlled trial published in the Journal of Cardiovascular Pharmacology (PMID: 29023286) enrolled 1,062 participants and found that 12 months of nattokinase supplementation produced measurable regression of carotid atherosclerotic plaques. The placebo group showed plaque progression. This is the kind of hard endpoint — actual imaging data — that matters.
Serrapeptase is a proteolytic enzyme isolated from Serratia marcescens, a bacterium found in the gut of silkworms. The silkworm uses it to dissolve its cocoon — a fact that gives you an intuitive sense of its ability to break down structural proteins.
Its primary mechanisms:
A 2018 review in Biotechnology and Applied Biochemistry (PMID: 30048004) documented serrapeptase's anti-inflammatory and fibrinolytic properties and its clinical applications in cardiovascular and surgical contexts. Unlike NSAIDs, serrapeptase does not inhibit prostaglandins, meaning it reduces inflammation without the gastrointestinal and cardiovascular side effects.
Nattokinase and serrapeptase attack arterial plaques through complementary mechanisms. Nattokinase dissolves the fibrin scaffold — the structural framework holding the plaque together. Serrapeptase degrades the dead cellular debris and softens the fibrous cap, making the fibrin structure accessible.
Think of it this way: nattokinase is the demolition crew, serrapeptase is the cleanup crew that removes the rubble the demolition exposes. Neither does the complete job alone as effectively as both together.
The biofilm-disrupting property of serrapeptase is particularly important. Calcified plaques develop a protective protein matrix that shields the fibrin core from enzymatic access. Serrapeptase degrades this matrix, exposing the plaque interior to nattokinase activity.
When arterial plaques are enzymatically degraded, calcium is liberated. Without proper redirection, this calcium can redeposit in soft tissue or contribute to hypercalcemia. This is where Vitamin D3 and Vitamin K2 (specifically MK-7) become critical co-factors, not optional additions.
Vitamin K2 activates matrix Gla protein (MGP), the body's primary calcium transport mechanism. MGP directs calcium out of arterial walls and into bones, where it belongs. A 2015 randomized trial in Thrombosis and Haemostasis (PMID: 25694037) showed that MK-7 supplementation significantly reduced arterial stiffness in postmenopausal women — precisely the population with the highest vascular calcium burden.
Vitamin D3 works synergistically with K2: D3 increases calcium absorption from the gut, K2 ensures it goes to bone rather than arteries. They are counterparts of the same system and should not be taken independently when addressing cardiovascular calcification.
The clinical research and practical application converge on this general framework:
Phase 1 — Primary Cleanse (months 1–3):
Nattokinase: 2,000–4,000 FU twice daily, away from meals
Serrapeptase: 120,000–250,000 SPU twice daily, fasted
D3: 5,000–10,000 IU daily with fat
K2 (MK-7): 200–400mcg daily
Phase 2 — Maintenance (months 4+):
Nattokinase: 2,000 FU once daily
Serrapeptase: 120,000 SPU once daily
D3/K2: continued at same doses
Critical timing note: Nattokinase has a plasma half-life of approximately 8 hours. Cardiovascular events are statistically most common in the early morning hours. Evening dosing is not arbitrary — it ensures peak fibrinolytic activity coincides with the highest-risk window.
Enzymes must be taken on an empty stomach. When taken with food, proteolytic enzymes are consumed digesting dietary protein rather than reaching systemic circulation. Minimum 45 minutes before eating, or 2 hours after.
This is not a 30-day fix. The carotid plaque regression data comes from 26-week and 12-month studies. Set realistic expectations:
The Vascular Cleanse Protocol included in our catalog documents a personal case: from 50% arterial blockage to clear vessels over approximately 3 years of consistent use. This is not a controlled trial — it is a field report. But it aligns precisely with what the mechanistic and clinical data would predict.
Both enzymes are well-tolerated in the literature. The primary consideration is anticoagulant interaction — nattokinase has additive fibrinolytic activity with warfarin, heparin, and antiplatelet medications. Patients on these medications should consult their physician before starting.
Serrapeptase is generally not recommended during active acute infection (its biofilm-disrupting activity could theoretically interfere with the body's containment of bacterial infection, though clinical evidence on this is limited).
Neither enzyme requires cycling. Unlike hormonal compounds, fibrinolytic enzymes do not cause receptor downregulation or feedback inhibition. Long-term continuous use is the appropriate model.
If you're going to do this seriously, measure it. Vascular imaging is not optional if you want to know whether the protocol is working.
The enzymes do the work. The imaging confirms it.
For the complete protocol — including the Lumbrokinase phase, exact sourcing recommendations, and the bloodwork monitoring schedule — see the Vascular Cleanse Protocol.
NattokinaseSerrapeptaseCardiovascularArterial HealthVascular Cleanse